Femara prescribing information |
|
 |
|
Femara notes
Letrozole sold under the brand name Femara is used to treat women suffering from breast cancer and who have attained menopause. Femara medication is more effective in treating breast cancer and thus advised instead of more commonly used anti-estrogen medication Tamoxifen. Femara breast cancer medication reduces the estrogen levels that slow down the growth of certain breast tumors. Just like Femara, Anastrozole found in medical stores under the brand name Arimidex is also administered to check breast cancer development. Femara for infertility problem has shown positive results and is used in an "off-label" fashion to treat infertility. Women are recommended to take Femara infertility curing drug nearing their menses that would decrease estrogen levels and increase substances and result in ovulation. Femara PCOS drug has shown positive results in treating women with Polycystic Ovary Syndrome. Femara endometriosis medication is very effective in checking estrogen levels thus checks progression of estrogen-dependent disease - endometriosis and the pain related to it.
One can experience Femara side effects like skin irritation, difficulty in breathing, swelling of face, lips, tongue, or throat, hot flashes, headache, muscle or joint pain, fatigue, night sweats, nausea, vomiting, etc. if one has been using Femara for treating breast cancer symptoms. You should consult your doctor and seek immediate medical help if you face any of the above side effects. Femara and pregnancy do not go together. Femara should never been taken by pregnant women as it damages the fetus. Femara is usually used in women who have crossed the childbearing age and reached menopause.
Femara should be taken once daily, with or without food (one 2.5-mg tablet a day). Femara should be continued as long as one finds growth in the tumour. It is best to take the guidance of your healthcare provider regarding dosage of Femara who would suggest exact dosage depending upon the severity of your breast cancer.
Description
The generic name of Femara is letrozole, which is a non-steroidal aromatase inhibitor. Femara is indicated for the treatment of hormonally responsive breast cancer and it acts by blocking the production of estrogen in human body, because of which the cancer cells stop growing. Apart from the treatment of breast cancer, Femara is also used for the treatment of endometriosis and some fertility doctors use it for ovarian stimulation. The dosage of Femara that is advised by doctors is about 2.5 mg in a single day and it can be taken without food too.
Description
Femara is an anti-estrogen medicinal drug that is utilized for the treatment of breast cancer in postmenopausal women. It was approved in the year 1997 by Food and Drug Administration of US for medicinal use.
Drug Mechanism
Femara functions by blocking the production of estrogen hormone in a female body because presence of estrogen in blood leads to the growth of cancer cells.
Dosage:
It is advised to consume Femara once in a day with or without food in form of tablets of 2.5 mg each.
Possible Side Effects
As per the studies the chances of possible side effects in case of Femara treatment are quite less when compared to other medicines. It may not be necessary that every woman who uses Femara feels its side effects but here are certain side effects that are common:
Vomiting
Nausea
Headache
Fatigue
Muscle pain
Pain in chest
Constipation
Diarrhoea
Caution
Femara is not recommended for pregnant women because it has a tendency to damage the Fetus. Therefore, it should be consumed by only those women who are no longer willing or able to give birth.
Ann Oncol. 2010 Jul 8. [Epub ahead of print]
Lψnning PE.
Analysis of aromatase inhibitors in breast cancer patients
J Clin Endocrinol Metab. 2010 Jul 7. [Epub ahead of print]
Drake MT
Study of bone resorption markers in post menopausal women
Curr Opin Obstet Gynecol. 2010 Aug;22(4):289-94.
Pritts EA.
Letrozole effective uses
J Physiol Biochem. 2009 Sep;65(3):267-75.
Yonden Z et all.
Effects of letrozone on bone biomarkers
Klin Onkol. 2009;22(6):268-72.
Kubatka P
Decrease in the risk of breast cancer by aromatase inhibitors
Am J Ther. 2009 Dec 19. [Epub ahead of print]
Montero AJ et all.
Analysis of gemcitabine and nab paclitaxel
Ther Clin Risk Manag. 2008 Dec;4(6):1295-304.
Untch M
Review of exemestane in breast cancer
Curr Opin Oncol. 2008 Sep;20(5):548-53.
Langdon SP
Ovarian cancer for for hormone therapy
Breast Cancer Res Treat. 2008 Dec;112 Suppl 1:35-43. Epub 2008 Dec 20.
Blackwell KL.
Department of Medicine, Division of Medical Oncology, Duke University Medical Center, P.O. Box 3893, Durham, NC 27710, USA. kimberly.blackwell@duke.edu
Similarity in aromatase inhibitors
Clin Breast Cancer. 2007 Dec;8 Suppl 1:S22-34.
Brufsky AM.
Administering bone loss in women in breast cancer
J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11.
Jakesz R et all.
Analysing anastrazole in post menopausal breast cancer patients
Clin Ter. 2007 Sep-Oct;158(5):441-52.
Viola G et all.
Treating local advanced breast cancer
Femara review article...
|
My Basket
